Literature DB >> 18984156

Nf1-dependent tumors require a microenvironment containing Nf1+/-- and c-kit-dependent bone marrow.

Feng-Chun Yang1, David A Ingram, Shi Chen, Yuan Zhu, Jin Yuan, Xiaohong Li, Xianlin Yang, Scott Knowles, Whitney Horn, Yan Li, Shaobo Zhang, Yanzhu Yang, Saeed T Vakili, Menggang Yu, Dennis Burns, Kent Robertson, Gary Hutchins, Luis F Parada, D Wade Clapp.   

Abstract

Interactions between tumorigenic cells and their surrounding microenvironment are critical for tumor progression yet remain incompletely understood. Germline mutations in the NF1 tumor suppressor gene cause neurofibromatosis type 1 (NF1), a common genetic disorder characterized by complex tumors called neurofibromas. Genetic studies indicate that biallelic loss of Nf1 is required in the tumorigenic cell of origin in the embryonic Schwann cell lineage. However, in the physiologic state, Schwann cell loss of heterozygosity is not sufficient for neurofibroma formation and Nf1 haploinsufficiency in at least one additional nonneoplastic lineage is required for tumor progression. Here, we establish that Nf1 heterozygosity of bone marrow-derived cells in the tumor microenvironment is sufficient to allow neurofibroma progression in the context of Schwann cell Nf1 deficiency. Further, genetic or pharmacologic attenuation of c-kit signaling in Nf1+/- hematopoietic cells diminishes neurofibroma initiation and progression. Finally, these studies implicate mast cells as critical mediators of tumor initiation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18984156      PMCID: PMC2788814          DOI: 10.1016/j.cell.2008.08.041

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  33 in total

Review 1.  The hallmarks of cancer.

Authors:  D Hanahan; R A Weinberg
Journal:  Cell       Date:  2000-01-07       Impact factor: 41.582

2.  Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis.

Authors:  G Bergers; R Brekken; G McMahon; T H Vu; T Itoh; K Tamaki; K Tanzawa; P Thorpe; S Itohara; Z Werb; D Hanahan
Journal:  Nat Cell Biol       Date:  2000-10       Impact factor: 28.824

3.  Neurofibromas in NF1: Schwann cell origin and role of tumor environment.

Authors:  Yuan Zhu; Pritam Ghosh; Patrick Charnay; Dennis K Burns; Luis F Parada
Journal:  Science       Date:  2002-05-03       Impact factor: 47.728

4.  MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis.

Authors:  L M Coussens; C L Tinkle; D Hanahan; Z Werb
Journal:  Cell       Date:  2000-10-27       Impact factor: 41.582

5.  Circulating growth factor levels are associated with tumorigenesis in neurofibromatosis type 1.

Authors:  George A Mashour; Pablo Hernáiz Driever; Melanie Hartmann; Stephanie N Drissel; Tingguo Zhang; Bianca Scharf; Ursula Felderhoff-Müser; Sadatoshi Sakuma; Reinhard E Friedrich; Robert L Martuza; Victor Felix Mautner; Andreas Kurtz
Journal:  Clin Cancer Res       Date:  2004-09-01       Impact factor: 12.531

6.  TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia.

Authors:  Neil A Bhowmick; Anna Chytil; David Plieth; Agnieszka E Gorska; Nancy Dumont; Scott Shappell; M Kay Washington; Eric G Neilson; Harold L Moses
Journal:  Science       Date:  2004-02-06       Impact factor: 47.728

Review 7.  Inflammation and cancer.

Authors:  Lisa M Coussens; Zena Werb
Journal:  Nature       Date:  2002 Dec 19-26       Impact factor: 49.962

8.  Loss of the nf1 tumor suppressor gene decreases fas antigen expression in myeloid cells.

Authors:  Kelly Hiatt; David A Ingram; Hannah Huddleston; Dan F Spandau; Reuben Kapur; D Wade Clapp
Journal:  Am J Pathol       Date:  2004-04       Impact factor: 4.307

9.  Hyperactivation of p21(ras) and the hematopoietic-specific Rho GTPase, Rac2, cooperate to alter the proliferation of neurofibromin-deficient mast cells in vivo and in vitro.

Authors:  D A Ingram; K Hiatt; A J King; L Fisher; R Shivakumar; C Derstine; M J Wenning; B Diaz; J B Travers; A Hood; M Marshall; D A Williams; D W Clapp
Journal:  J Exp Med       Date:  2001-07-02       Impact factor: 14.307

10.  Genetic and biochemical evidence that haploinsufficiency of the Nf1 tumor suppressor gene modulates melanocyte and mast cell fates in vivo.

Authors:  D A Ingram; F C Yang; J B Travers; M J Wenning; K Hiatt; S New; A Hood; K Shannon; D A Williams; D W Clapp
Journal:  J Exp Med       Date:  2000-01-03       Impact factor: 14.307

View more
  156 in total

Review 1.  Molecular mechanisms promoting the pathogenesis of Schwann cell neoplasms.

Authors:  Steven L Carroll
Journal:  Acta Neuropathol       Date:  2011-12-11       Impact factor: 17.088

Review 2.  The difficulty of targeting cancer stem cell niches.

Authors:  Mark A LaBarge
Journal:  Clin Cancer Res       Date:  2010-06-08       Impact factor: 12.531

3.  Back to the future: proceedings from the 2010 NF Conference.

Authors:  Susan M Huson; Maria T Acosta; Allan J Belzberg; Andre Bernards; Jonathan Chernoff; Karen Cichowski; D Gareth Evans; Rosalie E Ferner; Marco Giovannini; Bruce R Korf; Robert Listernick; Kathryn N North; Roger J Packer; Luis F Parada; Juha Peltonen; Vijaya Ramesh; Karlyne M Reilly; John W Risner; Elizabeth K Schorry; Meena Upadhyaya; David H Viskochil; Yuan Zhu; Kim Hunter-Schaedle; Filippo G Giancotti
Journal:  Am J Med Genet A       Date:  2010-12-22       Impact factor: 2.802

Review 4.  Pathogenesis of plexiform neurofibroma: tumor-stromal/hematopoietic interactions in tumor progression.

Authors:  Karl Staser; Feng-Chun Yang; D Wade Clapp
Journal:  Annu Rev Pathol       Date:  2011-11-07       Impact factor: 23.472

Review 5.  Multiple myeloma mesenchymal stem cells: characterization, origin, and tumor-promoting effects.

Authors:  Michaela R Reagan; Irene M Ghobrial
Journal:  Clin Cancer Res       Date:  2011-11-07       Impact factor: 12.531

6.  Marrow signal changes observed in follow-up whole-body MRI studies in children and young adults with neurofibromatosis type 1 treated with imatinib mesylate (Gleevec) for plexiform neurofibromas.

Authors:  Boaz Karmazyn; Mervyn D Cohen; Samuel Gregory Jennings; Kent A Robertson
Journal:  Pediatr Radiol       Date:  2012-06-22

7.  Neurofibroma-associated macrophages play roles in tumor growth and response to pharmacological inhibition.

Authors:  Carlos E Prada; Edwin Jousma; Tilat A Rizvi; Jianqiang Wu; R Scott Dunn; Debra A Mayes; Jose A Cancelas; Eva Dombi; Mi-Ok Kim; Brian L West; Gideon Bollag; Nancy Ratner
Journal:  Acta Neuropathol       Date:  2012-10-26       Impact factor: 17.088

8.  Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial.

Authors:  Kent A Robertson; Grzegorz Nalepa; Feng-Chun Yang; Daniel C Bowers; Chang Y Ho; Gary D Hutchins; James M Croop; Terry A Vik; Scott C Denne; Luis F Parada; Cynthia M Hingtgen; Laurence E Walsh; Menggang Yu; Kamnesh R Pradhan; Mary K Edwards-Brown; Mervyn D Cohen; James W Fletcher; Jeffrey B Travers; Karl W Staser; Melissa W Lee; Marcie R Sherman; Cynthia J Davis; Lucy C Miller; David A Ingram; D Wade Clapp
Journal:  Lancet Oncol       Date:  2012-10-23       Impact factor: 41.316

Review 9.  Neurofibromatosis-related tumors: emerging biology and therapies.

Authors:  Matthias A Karajannis; Rosalie E Ferner
Journal:  Curr Opin Pediatr       Date:  2015-02       Impact factor: 2.856

Review 10.  Influence of tumour micro-environment heterogeneity on therapeutic response.

Authors:  Melissa R Junttila; Frederic J de Sauvage
Journal:  Nature       Date:  2013-09-19       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.